Newsroom

September 2021

• Press release Sep 19, 2021

  Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

  With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
• Press release Sep 17, 2021

  Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)

  PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks…
• Press release Sep 17, 2021

  Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

  New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive…
• 
  Story Sep 14, 2021 Patient Perspectives

  Photographer Captures Patients Around the World Persevering With ITP

  To showcase how people living with ITP triumph and persevere, Novartis partnered with photographer Kate T. Parker on a series of photo essays.

• 
  Story Sep 14, 2021 Discovery

  Toward regrowing cartilage

  Novartis researchers aim to improve the lives of patients with osteoarthritis.

• 
  Story Sep 14, 2021 Access to Healthcare

  Doing the right thing is good business

  Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

• Press release Sep 13, 2021

  Novartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer

  Biologics License Application (BLA) submission supported by Phase III RATIONALE 302 trial, which met primary endpoint of improvement in overall survival (OS) in people with advanced or metastatic…
• Press release Sep 08, 2021

  Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine

  Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading…
• 
  Story Sep 03, 2021 Patient Perspectives

  A blood cancer patient’s long road to diagnosis

  Ilona, a patient living with polycythemia vera, shares her experiences with this rare blood cancer

• Pulse Update Sep 03, 2021

  Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients

• Press release Sep 03, 2021

  Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions

  Novartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair® Breezhaler® (IND/GLY/MF*) and Atectura® Breezhaler® (IND/MF**) — for…
• Pulse Update Sep 02, 2021

  Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee